Robert G. Maki, M.D., Ph.D. talks about how molecular clues help refine Kinase Inhibitor strategy for GI. In the post-imatinib (Gleevec) era, treatment of gastrointestinal stromal tumors has shifted from serial surgeries to refinement of kinase inhibitor dosing, according to this presentation from the ASCO-GI symposium here.
